Penumbra, Inc. reported financial results for the first quarter ended March 31, 2022, with revenue of $203.9 million, an increase of 20.5% compared to the first quarter of 2021.
Total revenue increased to $203.9 million for the first quarter of 2022 compared to $169.2 million for the first quarter of 2021, an increase of 20.5%.
Revenue from sales of vascular products grew to $122.8 million for the first quarter of 2022, an increase of 37.7%.
Revenue from sales of neuro products grew to $81.1 million for the first quarter of 2022, an increase of 1.3%.
Gross profit was $127.4 million, or 62.5% of total revenue for the first quarter of 2022.
No forward guidance was provided in the earnings report.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance